Professor, Medicine, University of Wisconsin Medical School
Oncology
Dr. Howard H. Bailey, MD
|
|
Give Review
Howard H. Bailey practices Oncology. He went to University of North Dakota School of Medicine and Health Sciences. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Howard Bailey is a published doctor. He published 31 publications, including: 'Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology.' He is registered with Medicare and accepts Medicare payments.
Publications
- Clinical Cancer advances 2015: annual report on progress against Cancer from the american society of clinical oncology.
- Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern u.s. Population.
- A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced Cancer.
- Cancer chemoprevention is not a failure.
- Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder Cancer.
- A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
- A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid Tumors.
- Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
- Predictors of Willingness to Participate in Window-of-Opportunity Breast Trials.
- Inpatient Hospitalization of Oncology Patients: Are We Missing an Opportunity for End-of-Life Care?
- Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1?-hydroxyvitamin D2 in patients with clinically localized prosta...
- A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity.
- Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) ...
- Enhancing the bioavailability of resveratrol by combining it with piperine.
- Maintenance rituximab following inDuction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
- Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
- AIDS-related Kaposi's sarcoma of the gastrointestinal Tract.
- Metastatic soft tissue Sarcoma diagnosed by small bowel video capsule endoscopy.
- A randomized, double-blind, placebo-controlled phase 3 skin Cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin Cancer.
- Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine.
- Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid Tumors.
- Phase II study of daily oral perifosine in patients with advanced soft tissue Sarcoma.
- A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian Cancer: a Gynecologic Oncology Group study.
- Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
- Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.
- Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate Cancer.
- Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
- A phase II trial of daily perillyl alcohol in patients with advanced ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96.
- Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
- Green Tea Polyphenols and Cancer Chemoprevention of Genitourinary Cancer.
Schools
University Of North Dakota School Of Medicine
Smahec
University Wisc Clin Cancer Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- American Enterprise Group
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Preferred Plus POS
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- Health Alliance PPO
- Choice Care PPO
- Preferred PPO
- Medicare MCR
- Thrivent Financial
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Wisconsin -
Michigan State University at Kalamazoo -
University of North Dakota School of Medicine and Health Sciences
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER | 1861468936 | |
| NPPES Provider LastName | BAILEY | |
| NPPES Provider FirstName | HOWARD | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 142.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 18.0 | |
| Percent Opioid Claims | 12.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861468936 |
| Last Name Of The Provider | BAILEY |
| First Name Of The Provider | HOWARD |
| View All |
Similar Doctors
|
|
Dr. Shannon E. O'Mahar, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Murtuza M. Rampurwala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark E. Burkard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Danielle B. Bol-De Greve, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ticiana B. Leal, MD
This Doctor is OpenDoctor Recommended.
|